XDNA news

Kelly CRISPR & Gene Editing Technology · Biotechnology · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

24/7 Wall St. · 28 Oct 2026, 22:00 UTC
Thermo Fisher Scientific Reaches $704 and a New 52-Week High
9.9% of XDNA
News-Medical.net · 28 Oct 2026, 17:31 UTC
Hot-melt extrusion in pharmaceutical implant manufacturing
9.9% of XDNA
The Manila times · 28 Oct 2026, 20:27 UTC
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8.7% of XDNA
Morningstar · 28 Oct 2026, 14:15 UTC
TMO - Thermo Fisher Scientific Inc Analysis
9.9% of XDNA
Where to buy XDNA
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 27 Oct 2026, 17:10 UTC
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript | Seeking Alpha
13.4% of XDNA
The Manila times · 28 Oct 2026, 02:46 UTC
15-year-old Designs Low-Cost Device to Monitor Airborne Bacteria in the Environment; Wins $25,000 Top Award at the 2026 Thermo Fisher Scientific Junior Innovators Challenge
9.9% of XDNA
Where to buy XDNA
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Yahoo! Finance · 28 Oct 2026, 07:29 UTC
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie
7.1% of XDNA
Yahoo! Finance · 28 Oct 2026, 16:03 UTC
This Dividend Powerhouse Is Heading Into Q3 Earnings With Plenty at Stake
4.0% of XDNA
Benzinga · 26 Oct 2026, 17:27 UTC
Billionaire Investor Adds to Danaher Stake After Cutting It Earlier This Year - Danaher (NYSE:DHR)
14.0% of XDNA
Seeking Alpha · 28 Oct 2026, 08:28 UTC
AbbVie: Still Strong Growth, But Patent Cliff Getting Closer (NYSE:ABBV) | Seeking Alpha
4.0% of XDNA
wallstreet:online · 28 Oct 2026, 14:05 UTC
Sandoz reports strong biosimilar-sales momentum; narrowed full-year net-sales range and upgrade to margin guidance
3.1% of XDNA
Seeking Alpha · 28 Oct 2026, 12:00 UTC
Sandoz Group AG (SDZNY) Q3 2026 Sales/Trading Call Transcript | Seeking Alpha
3.1% of XDNA
The Manila times · 28 Oct 2026, 11:10 UTC
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
3.1% of XDNA
The Wall Street Journal · 28 Oct 2026, 09:49 UTC
Sandoz Shares Fall After Company Turns Cautious on Sales Guidance
3.1% of XDNA
Investing.com · 28 Oct 2026, 09:35 UTC
Earnings call transcript: Sandoz narrows 2026 sales view after strong Q3 By Investing.com
3.1% of XDNA
Bloomberg Business · 28 Oct 2026, 09:34 UTC
Sandoz Warns EU May Scrap Antibiotic Protection, Risking Plant
3.1% of XDNA
Investing.com · 28 Oct 2026, 08:36 UTC
Why is Sandoz stock sliding today? By Investing.com
3.1% of XDNA
RTTNews · 28 Oct 2026, 07:56 UTC
Sandoz Q3 Sales Rise 4%; Cuts Annual Sales Growth Outlook, But Ups Profit Margin View
3.1% of XDNA
Reuters · 28 Oct 2026, 06:52 UTC
Generic drugmaker Sandoz lowers sales outlook, lifts profit forecast
3.1% of XDNA
CNBC · 27 Oct 2026, 18:00 UTC
I just bought this pharma stock for its next generation of blockbuster drugs -- and its dividend
4.0% of XDNA

XDNA news

Where to buy XDNA

Where to buy XDNA